IL-23: a promising therapeutic target for systemic lupus erythematosus

Arch Med Res. 2010 Apr;41(3):221-5. doi: 10.1016/j.arcmed.2010.02.011.

Abstract

Cytokine-mediated immunity plays a crucial role in the pathogenesis of various autoimmune diseases including systemic lupus erythematosus (SLE). The recent identification of the dimeric interleukin (IL)-12-related cytokine IL-23 now contributes to our understanding of the fine-tuning of cellular immunity. The critical implication of IL-12 p40 in autoimmune inflammation has long been misinterpreted and until recently have studies revealed that it is IL-23, not IL-12, is the crucial factor in this immune dysregulation. Therefore, targeting of IL-23 or the IL-23 receptor is a potential therapeutic approach for autoimmune diseases including SLE. In this opinion article, we will discuss the biological features of IL-23 and summarize recent advances on the role of IL-23 in the pathogenesis and treatment of SLE.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmunity
  • Encephalomyelitis, Autoimmune, Experimental / etiology
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Humans
  • Inflammation / etiology
  • Inflammation / immunology
  • Interleukin-23 / agonists
  • Interleukin-23 / antagonists & inhibitors
  • Interleukin-23 / immunology*
  • Lupus Erythematosus, Systemic / etiology
  • Lupus Erythematosus, Systemic / immunology*
  • Lupus Erythematosus, Systemic / therapy*
  • Mice
  • Receptors, Interleukin / immunology
  • Signal Transduction / immunology
  • T-Lymphocyte Subsets / immunology

Substances

  • IL23R protein, human
  • Interleukin-23
  • Receptors, Interleukin